TechCrunch AI · 10/21/2026, 04:35:10
OpenAI Acquires Orchestra Bio to Strengthen Biotech AI Capabilities
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup, to bolster its capabilities in the life sciences sector. The team and technology will be integrated into OpenAI's Rosalind model and Workbench tool to streamline drug discovery operations. This move highlights how major LLM providers are increasingly acquiring vertical-specific startups to build industry-tailored software ecosystems.
SOURCE COVERAGEFull Original Report
Image Credits:FotografiaBasica (opens in a new window) / Getty Images
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.